DARZALEX ® + Rd or Vd after rst relapse
in multiple myeloma
DISCOVER
DARZALEX
®
(daratumumab)
the rst and only CD38-directed
monoclonal antibody (mAb) 1
Indication
DARZALEX ® (daratumumab) is indicated in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone,
for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Rd=lenalidomide and dexamethasone; Vd=bortezomib and dexamethasone.
Important Safety Information
Warnings and precautions include: infusion reactions, interference with serological testing, neutropenia, thrombocytopenia, and
interference with determination of complete response.
In patients who received DARZALEX ® in combination with lenalidomide and dexamethasone, the most frequently reported adverse
reactions (incidence ≥20%) were: neutropenia (92%), thrombocytopenia (73%), upper respiratory tract infection (65%), infusion reactions
(48%), diarrhea (43%), fatigue (35%), cough (30%), muscle spasms (26%), nausea (24%), dyspnea (21%) and pyrexia (20%). The overall
incidence of serious adverse reactions was 49%. Serious adverse reactions were: pneumonia (12%), upper respiratory tract infection (7%),
in uenza (3%) and pyrexia (3%).
In patients who received DARZALEX ® in combination with bortezomib
and dexamethasone, the most frequently reported adverse reactions
(incidence ≥20%) were: thrombocytopenia (90%), neutropenia (58%),
peripheral sensory neuropathy (47%), infusion reactions (45%), upper
respiratory tract infection (44%), diarrhea (32%), cough (27%), peripheral
edema (22%), and dyspnea (21%). The overall incidence of serious
adverse reactions was 42%. Serious adverse reactions were: upper
respiratory tract infection (5%), diarrhea (2%) and atrial brillation (2%).
Please see Important Safety Information and brief summary
of full Prescribing Information on following pages.